Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending-dose study of ACT-541468 in healthy men
NL-OMON41910Phase 1Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Insomnia and sleep disorder comparing ACT-541468 with Placebo (2 arms). Primary endpoints: Plasma and whole blood concentrations of ACT-541468, metabolites, and radioactivity, Dose proportionality and 8 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
daridorexant
03
Conditions
Insomniasleep disorder
Beyond the preview
Go deeper on NL-OMON41910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41910.